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Abstract 
Angiotensin-converting enzyme-2 (ACE-2) is a homolog of ACE that preferentially forms 
angiotensin-(ANG)-1-7 from angiotensin II (ANG II). We investigated the cardioprotective 
effects of telmisartan, a well-known angiotensin receptor blockers (ARBs) against experi-
mental autoimmune myocarditis (EAM). EAM was induced in Lewis rats by immunization with 
porcine cardiac myosin. The rats were divided into two groups and treated with telmisartan 
(10 mg/kg/day) or vehicle for 21 days. Myocardial functional parameters were significantly 
improved by treatment with telmisartan compared with vehicle-treated rats. Telmisartan 
lowered  myocardial  protein  expressions  of  NADPH  oxidase  subunits  3-nitrotyrosine, 
p47phox, p67 phox, Nox-4 and superoxide production significantly than vehicle-treated rats. 
In contrast myocardial protein levels of ACE-2, ANG 1-7 mas receptor were upregulated in 
the telmisartan treated group compared with those of vehicle-treated rats. The myocardial 
protein  expression  levels  of  tumor  necrosis  factor  receptor  (TNFR)-associated  factor 
(TRAF)-2, C/EBP homologous protein (CHOP) and glucose-regulated protein (GRP) 78 were 
decreased in the telmisartan treated rats compared with those of vehicle-treated rats. In 
addition,  telmisartan  treatment  significantly  decreased  the  protein  expression  levels  of 
phospho-p38 mitogen-activated protein kinase (MAPK), phospho-JNK, phospho-ERK and 
phospho (MAPK) activated protein kinase-2 than with those of vehicle-treated rats. Moreover, 
telmisartan significantly decreased the production of proinflammatory cytokines, myocardial 
apoptotic markers and caspase-3 positive cells compared with those of vehicle-treated rats. 
Therefore, we suggest that telmisartan was beneficial protection against heart failure in rats, at 
least in part by suppressing inflammation, oxidative stress, ER stress as well as signaling 
pathways through the modulation of ACE2/ANG1-7/Mas receptor axis.  
Key words: Experimental autoimmune myocarditis; endoplasmic reticulum stress; inflammation; 
telmisartan; oxidative stress; signaling pathways 
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Introduction 
Inflammation and autoimmunity are involved in 
many cardiac diseases. In humans, acute myocarditis 
is a potentially lethal disease that frequently precedes 
the development of dilated cardiomyopathy (DCM). 
There have been two mechanisms by which myocar-
ditis develop into DCM have been proposed: one is 
persistent viral infection and the other is progressive 
autoimmune  myocardial  injury  [1].  Some  cases  of 
myocarditis  may  be  mediated  by  autoimmune  re-
sponse to cardiac antigens. Experimental autoimmune 
myocarditis  (EAM)  in  rodents  may  be  elicited  by 
immunization  of  cardiac  myosin,  and  EAM  in  rats 
mimics  human  fulminant  myocarditis  in  the  acute 
phase and human DCM in the chronic phase [2]. EAM 
is  induced  by  T  cell  activation  and  the  peak  of  in-
flammation is  observed  in the heart around day 21 
after immunization [3-4]. Some evidence supports a 
role  of  cellular  immune  mechanisms  in  the  patho-
genesis of myocarditis and subsequent DCM [5]. 
The  renin-angiotensin-aldosterone  system 
(RAAS) plays an important role in the pathogenesis of 
a variety of clinical conditions, including atheroscle-
rosis, hypertension, left ventricular (LV) hypertrophy, 
myocardial  infarction,  and  heart  failure  [6-7].  As  a 
result, the RAAS represents a logical therapeutic tar-
get in the management of hypertension, renal disease, 
and  cardiovascular  disease.  Recently,  a  new  axis  of 
RAAS has been established. In this axis, angiotensin 
converting enzyme-2 (ACE-2) is a key component of 
the  renin-angiotensin  system  (RAS)  and  catalyzes 
with high efficiency the conversion of angiotensin-II 
(ANG-II) to angiotensin 1-7 (ANG 1–7) and stimulates 
the  G-protein  coupled  receptor  termed  Mas,  which 
has been shown to prevent ANG-II-induced cardio-
vascular hypertrophy and remodeling associated with 
blockade of MAPK signaling [8-12]. ACE-2 is reported 
to be highly expressed in the heart and kidney. ACE-2 
is a membrane-associated  hydrolase and it  also hy-
drolyzes ANG I to ANG 1–9 [13]. As ANG 1–9 can be 
converted to ANG 1–7 by ACE or by other peptidases, 
ACE-2 facilitates ANG 1–7 production by two sepa-
rate pathways [14]. It has been demonstrated previ-
ously that there are reduced ACE-2 levels in cardio-
vascular  system  in  spontaneously  hypertensive  rats 
and  in  a  rat  model  of  myocardial  infarction  while 
overexpression of ACE-2 contributes to the attenua-
tion of cardiovascular damage in these rats [10, 15-17]. 
An understanding of the regulation of these enzymes 
is clinically relevant in view of recent studies showing 
that ACE-2/ANG 1-7 expression is altered in patho-
logical conditions such as diabetes, hypertension, and 
cardiovascular diseases [18-20].  
However, recent studies indicated that ANG 1–7 
has more active roles in RAAS. ANG 1–7 causes vas-
odilation, which antagonizes AT1-receptor mediated 
vasoconstriction. This effect seemed to be  mediated 
by the bradykinin–NO (nitric oxide) pathway [13, 21]. 
Recently,  Ishiyama  et  al.,  reported  that  olmesartan 
increased ACE-2 expression in the remodeling heart 
after myocardial infarction, which theoretically could 
contribute to the beneficial effects of ARB by facili-
tating  increased  cardiac  ANG  1-7  formation  [22].  It 
has  also  been  reported  that  telmisartan  induced  a 
significant increases of ACE-2 gene and protein ex-
pressions in the myocardium of pressure-overloaded 
rats  and  also  attenuates  vascular  hypertrophy  in 
spontaneously hypertensive rats by the modulation of 
ACE-2 expression with a marked reversal of ERK1/2 
and JNK phosphorylation signaling pathways [23-24]. 
Collectively, these results suggest that ANG 1–7 an-
tagonized  the  pressor  effect  mediated  by 
AT1-receptor  stimulation,  thereby  resulting  in  a 
blood-pressure-lowering  effect  and  an  or-
gan-protective effect, such as a reduction of cardiac 
hypertrophy and fibrosis and renal damage.  
Despite many reports show the beneficial effect 
of  ARBs  in  cardiovascular  diseases  [1-7,  11,  18-20, 
22-24]. To date, few studies have examined the bene-
ficial  effects  of  telmisartan  on  this  new  axis  of 
ACE-2/ANG  1–7/Mas  receptor  in  cardiovascular 
diseases [23-25], but its effectiveness on this new axis 
of ACE-2/ANG 1–7/Mas receptor in a rat model of 
EAM is not yet  known. The present study was de-
signed  to  assess  the  cardioprotective  effects  of 
telmisartan on cardiac function using hemodynamic 
and  echocardiographic  parameters,  neurohumoral 
factors  such  as  serum  ANG  1-7  and  inflammation, 
oxidative  stress,  endoplasmic  reticulum  (ER)  stress, 
myocardial apoptosis and signaling pathways in a rat 
model  heart failure after EAM.  Our findings reveal 
that  administration  of  telmisartan  attenuates  myo-
cardial  remodeling  in  EAM  rats  by  modulation  of 
ACE-2/ANG  1-7/Mas  receptor  expression  with  a 
marked  reversal  of  inflammatory  events  and  stress 
signaling. 
Materials and Methods 
Chemicals 
Unless otherwise stated, all reagents were of an-
alytical grade and were purchased from Sigma (To-
kyo, Japan). Telmisartan was generously provided by 
Boehringer  Ingelheim  GmbH  (Ingelheim  am  Rhein, 
Germany). Int. J. Biol. Sci. 2011, 7 
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Animals 
Lewis rats (male, 8 weeks old) were purchased 
from Charles River Japan Inc. (Kanagawa, Japan). All 
experiments were performed in accordance with the 
guidelines of our institute [26]. Animals were kept in 
the  departmental  animal  house  under  controlled 
conditions of 25±2 °C, relative humidity of 60±5% and 
a light–dark cycle of 12:12 h. They were fed with food 
pellets  (Oriental  Yeast  Co.,  Ltd,  Tokyo,  Japan)  and 
water ad libitum. 
Immunization and treatment protocol 
Lewis  rats  were  injected  in  the  footpads  with 
antigen-adjuvant  emulsion  according  to  the  proce-
dure  described  previously.  In  brief,  porcine  cardiac 
myosin was dissolved in phosphate-buffered saline at 
5  mg/ml  and  emulsified  with  an  equal  volume  of 
complete  Freund’s  adjuvant  with  11  mg/ml  Myco-
bacterium  tuberculosis  H37RA  (Difco  Lab.,  Detroit, 
MI, USA). EAM was induced in rats by immunization 
with 0.1 ml emulsion once by subcutaneous injection 
into their rear footpads (0.1 ml to each footpad). The 
morbidity of EAM was 100% in rats immunized by 
this procedure [2, 26]. After immunization, the Lewis 
rats were divided into two groups and received oral 
administration  of  telmisartan  (10  mg/kg/day; 
Group-Tel-10) or vehicle (Group-EAM) for 21 days. 
Age-matched Lewis rats without immunization were 
used as normal controls (Group-N). The doses used in 
the experiments were determined on the basis of an-
ti-inflammatory  and  antifibrotic  properties  of 
telmisartan as previously reported [26, 27]. We have 
reported that telmisartan (10 mg/kg/day) improved 
cardiac function and attenuated oxidative stress, car-
diac  remodeling  (fibrosis  and  hypertrophy)  and  in-
flammatory mediators in rats with heart failure after 
EAM [26, 27].  
Assessment of myocardial functions by hemo-
dynamic and echocardiographic studies 
To  obtain  hemodynamic  data,  rats  were  anes-
thetized with 2% halothane in oxygen during the sur-
gical  procedures.  A  catheter-tip  transducer  (Miller 
SPR  249;  Miller  Instruments,  Houston,  TX)  was  in-
troduced into the left ventricle through the right ca-
rotid artery to determine peak LV pressure (LVP) and 
LV end-diastolic pressure (LVEDP), and the rates of 
intraventricular  pressure  rise  and  decline  (±dP/dt) 
were recorded as described previously [26]. After in-
strumentation,  the  concentration  of  halothane  was 
reduced to 0.5% to minimize the effects of the anes-
thetic on hemodynamic parameters. In addition, mean 
blood pressure (MBP) was measured in conscious rats 
by  using  the  tail-cuff  plethysmographic  method 
[Softron  BP-98A,  Tokyo,  Japan].  Echocardiographic 
studies were carried out with a 7.5-MHz transducer 
(Aloka Inc., Tokyo, Japan). The LV dimensions in di-
astole and systole and percent fractional shortening 
were estimated using the M-mode measurements.  
Cardiac morphometric parameters 
The  body  weight  (BW)  of  rats  was  noted  just 
before the surgical procedure. After the hemodynamic 
and echocardiographic analyses, the rats were sacri-
ficed, and the myocardium was isolated and weighed 
to calculate the ratio of heart weight to body weight 
(HW/BW).  
Measurement of ANG 1-7 by Enzyme-linked 
immunosorbent assay (ELISA) 
Serum concentrations of ANG 1-7 was measured 
by using ELISA kits (Peninsula Laboratories, Belmont, 
CA) according to the manufacturer's instructions.  
Immunohistochemical determination of myo-
cardial angiotensin converting enzyme (ACE-2), 
Angiotensin (ANG 1-7) mas receptor 
Formalin-fixed,  paraffin-embedded  cardiac  tis-
sue  sections  were  used  for  immunohistochemical 
staining.  After  deparaffinization  and  hydration,  the 
slides  were washed in Tris-buffered saline (TBS; 10 
mM/l Tris HCl, 0.85% NaCl, pH 7.5) containing 0.1% 
bovine serum albumin (BSA). Endogenous peroxidase 
activity  was  quenched  by  incubating  the  slides  in 
methanol  and  0.6%  H2O2  in  methanol.  For  antigen 
retrieval, the sections were pretreated with trypsin for 
15 min at 37 °C. After overnight incubation with the 
primary antibody, i.e., rabbit polyclonal anti-ANG 1-7 
mas receptor (diluted 1:100) (Alomone Labs Ltd, Je-
rusalem, Israel) antibody; goat polyclonal anti-ACE-2 
(diluted  1:100)  (Santa  Cruz  Biotechnology,  Santa 
Cruz, CA, USA) at 4 °C, the slides were washed in 
TBS,  horseradish  peroxidase  (HRP)-conjugated  sec-
ondary antibody was then added, and the slides were 
further  incubated  at  room  temperature  for  45  min. 
The slides were washed in TBS, incubated with dia-
minobenzidine  tetrahydrochloride  as  the  substrate, 
and  counterstained  with  hematoxylin.  A  negative 
control without primary antibody was included in the 
experiment to verify the antibody specificity.  
Immunofluorescence determination of glucose 
regulated protein-78 (GRP-78) and caspase-3 
For  immunofluorescence,  tissues  were  fixed  in 
10% buffered formaldehyde solution and embedded 
in  paraffin.  Sections  underwent  microwave  antigen 
retrieval, were blocked with 10% respective serums in 
phosphate-buffered saline, and were incubated with 
polyclonal  goat  anti-  glucose  regulated  protein-78 Int. J. Biol. Sci. 2011, 7 
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(GRP-78) antibody (Santa Cruz Biotechnology); poly-
clonal rabbit anti-caspase-3 antibody (Cell Signaling 
Technology).  Binding  sites  of  the  primary  antibody 
were  revealed  with  fluorescein  isothiocya-
nate-conjugated secondary antibody (Sigma–Aldrich, 
St. Louis, MO, USA). Samples were visualized with a 
fluorescence  microscope  at  100X  magnification 
(CIA-102; Olympus) [30]. 
In situ detection of superoxide production in 
hearts 
To evaluate in situ superoxide production from 
hearts, unfixed frozen cross sections of the specimens 
were stained with dihydroethidium [DHE; Molecular 
Probes, Eugene, OR, USA] according to the previously 
validated method [28, 29]. Briefly, the unfixed frozen 
tissues were cut into 10-μm-thick sections and incu-
bated  with  10  μM  DHE  at  37  °C  for  30  min  in  a 
light-protected  humidified  chamber.  Fluorescence 
images  were  obtained  using  a  fluorescence  micro-
scope equipped with a rhodamine filter. In the pres-
ence of superoxide, DHE is converted to the fluores-
cent molecule ethidium, which can then label nuclei 
by intercalating with DNA. 
Western Immunoblotting  
Myocardial  tissue  samples  obtained  from  dif-
ferent  groups  were  homogenized  with  lysis  buffer. 
Protein concentrations in these homogenized samples 
were measured by the bicinchoninic acid method. For 
Western blots, proteins were separated by SDS-PAGE 
and identified with the following antibodies to quan-
tify the myocardial levels of proteins: anti-Nox-4, an-
ti-p67phox,  anti-ACE-2,  anti-cyclooxygenase-2 
(Cox-2),  anti-tumor  necrosis  factor-α  (TNF-α),  an-
ti-glucose  regulated  protein-78  (GRP-78)  and  an-
ti–glyceraldehyde-3-phosphate  dehydrogenase 
(GAPDH)  goat  polyclonal  antibodies;  anti-p47phox, 
anti-p38  mitogen-activated  protein  kinase  (p38 
MAPK),  anti-phospho-p38  MAPK,  an-
ti-c-Jun-N-terminal  kinase  (JNK),  anti-phospho-JNK, 
anti-ERK,  anti-phospho-ERK,  anti-p38 
MAPK-activated  protein  kinase-2,  anti-phospho-p38 
MAPK-activated mitogen kinase-2, anti-tumor necro-
sis factor receptor (TNFR)-associated factor (TRAF)-2, 
anti-NF-kB,  anti-caspase-3,  anti-caspase-7  and  an-
ti-ANG 1-7 mas receptor rabbit polyclonal antibody 
and  anti-C/EBP  homologous  protein  (CHOP),  an-
ti-iNOS,  anti-Bcl-2  and  anti-3-nitrotyrosine  (3-NT) 
mouse polyclonal antibody (Santa Cruz Biotechnolo-
gy).  We  used  10%  sodium  dodecyl  sul-
fate-polyacrylamide gel electrophoresis (Bio-Rad, CA, 
USA), and electrophoretically transferred to nitrocel-
lulose membranes. Membranes were blocked with 5% 
nonfat dry milk and 3% BSA (Sigma, St Louis, USA) in 
TBS-T (20 mM/l Tris, pH 7.6, 137 mM/l NaCl, and 
0.05% Tween). After incubation with the primary an-
tibody, the bound antibody was visualized with the 
respective  HRP-coupled  secondary  antibody  (Santa 
Cruz  Biotechnology)  and  chemiluminescence  devel-
oping  agents  (Amersham  Biosciences,  Buckingham-
shire,  UK).  The  level  of  GAPDH  was  estimated  in 
every sample to check for equal loading of the sample. 
Films were scanned, and band densities were quanti-
fied with densitometric analysis using the Scion Im-
age program (GT-X700, Epson, Tokyo, Japan).  
Statistical analysis 
All values are expressed as the means ± S.E.M. 
Statistical analysis of differences between the groups 
was  performed  by  one-way  ANOVA,  followed  by 
Tukey’s  or  Bonferroni’s  method  and  the  two  tailed 
t-test when appropriate. P < 0.05 was considered as 
significant. For statistical analysis, GraphPad Prism 5 
software (San Diego, CA, U.S.A) was used. 
Results 
Effects of telmisartan on myocardial functions 
Although the heart rate was not different among 
the  three  groups  of  rats,  central  venous  pressure 
(CVP) and LVEDP were significantly higher (5.98±0.6 
vs 0.52±0.5 mm Hg (P < 0.01); 19.24±1.6 vs 4.12±5.6 
mm Hg (P < 0.01), respectively) and ±dP/dt was sig-
nificantly lower in vehicle-treated rats than in group 
N  (2316±236  vs  7568±1046  mm  Hg/s  (P  <  0.01); 
2088±194 vs 7356±1560 mm Hg/s (P < 0.01), respec-
tively), indicating systolic and diastolic dysfunction in 
vehicle-treated rats (Table 1). CVP and LVEDP were 
decreased more significantly in the telmisartan treat-
ed  group  compared  with  those  in  vehicle-treated 
group. Myocardial contractility  parameters (rates of 
intraventricular pressure rise and decline) were also 
improved  in  EAM  rats  treated  with  telmisartan.  In 
addition,  MBP  were  significantly  lowered  in  vehi-
cle-treated rats than in group N rats and were mar-
ginally increased by treatment with telmisartan. 
Echocardiographic studies showed increased LV 
dimensions in diastole and systole (7.8±0.8 vs 7.2±1.4 
mm; 6.8±0.58 vs 3.8±0.36 mm (P < 0.01), respectively), 
and  reduced  fractional  shortening  (FS)  (17.4±3.2  vs 
41.5±2.5%  (P  <  0.01)  and  ejection  fraction  (EF) 
(38.0±10.5 vs 78.4±5.2% (P < 0.01) in group V rats, in-
dicating  impaired  systolic  function  compared  with 
group  N  rats  (Table  1).  Treatment  with  telmisartan 
more significantly decreased LV dimensions in sys-
tole and increased FS and EF when compared with 
those of vehicle-treated rats (Table 1 and Fig. 1). Int. J. Biol. Sci. 2011, 7 
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Effects of telmisartan on morphometric param-
eters 
HW and the ratio of HW/BW were significantly 
larger in group EAM than in group N rats (1.54±0.12 
vs 1.20±0.05 g/kg (P < 0.01); 5.9±0.25 vs 3.5±0.14 g/kg 
(P < 0.01), respectively; Table 2). Telmisartan signifi-
cantly reduced HW and the ratio of HW/BW when 
compared with those of vehicle-treated rats (Table 2). 
Effects of telmisartan on serum ANG 1-7 levels 
Serum  ANG  1-7  concentrations  were  signifi-
cantly decreased in vehicle-treated rats in comparison 
with those in group N rats (1.14±1.2 vs 0.73±0.8 ng/ml 
(P  <  0.01)).  Treatment  with  telmisartan  further  ele-
vated the serum concentration  of ANG 1-7 in com-
parison with those of vehicle-treated rats (Table 1). 
Effects of telmisartan on inflammatory markers 
The myocardial protein levels of NF-kB, Cox-2, 
TNF-α  and  iNOS  were  significantly  upregulated  in 
group EAM rats (1.9, 2.4, 2.8 and 2.4-fold, respective-
ly)  compared  with  group  N  rats  (Fig.  2A-2E). 
Telmisartan  treatment  significantly  downregulated 
the protein levels of NF-kB, Cox-2, TNF-α and iNOS 
(2.9, 1.4, 1.4 and 3.6-fold, respectively) in the myocar-
dium  compared  with  those  of  vehicle-treated  rats 
(Fig. 2A-2E).  
 
 
Table 1 Changes in hemodynamic and echocardiographic functional parameters after 3 weeks of treatment with telmisartan 
in rats with or without experimental autoimmune myocarditis 
Functional parameters  Group N (n=4)  Group EAM (n=6)  Group Tel-10 (n=6) 
CVP (mmHg)  0.60±0.3  5.12±0.6**  2.14±1.2## 
MBP (mmHg)    94±8.0  80±10.0*  84±7.0* 
LVP (mmHg)  112±4.0   74±7.0**  84±4.8**# 
LVEDP (mmHg)  4.52±5.0  17.0±1.5**  9.5±5.6**## 
+dP/dt (mmHg/s)  7456±954  2554±236**  3704±335** 
-dP/dt (mmHg/s)  7244±1322  2300±194**  3122±418** 
HR (beats/min)  355±8.3  301±19.5  296±19.8 
LVDd (mm)  6.8±1.4  7.5±1.2  7.2±0.5 
LVDs (mm)  3.5±0.5  7.2±0.8**  5.5±0.70# 
FS (%)  38.5±2  19.5±3.8**  30.7±5.4## 
EF (%)  72.4±5.5  39.8±8.2**  62.56±6.8## 
 Results are presented as the mean ± S.E.M. CVP, central venous pressure; MBP, mean blood pressure; LVP, left ventricular pressure; 
LVEDP, left ventricular end-diastolic pressure; {plus minus} dP/dt, rate of intra-ventricular pressure rise and decline; HR, heart rate; LVDd, 
left ventricular dimension in diastole; LVDs, left ventricular dimension in systole; FS, fractional shortening; EF, ejection fraction; group N, 
aged matched untreated rats; group EAM, rats with heart failure treated with vehicle; group Tel-10, rats with heart failure treated with 
telmisartan 10 mg/kg/day respectively; * P < 0.05 and ** P < 0.01 vs group N; # P < 0.05 and ## P < 0.01 vs group EAM. 
 
 
Table 2 Changes in morphometric and histopathological parameters and serum angiotensin 1-7 level after 3 weeks of 
treatment with telmisartan in rats with or without experimental autoimmune myocarditis  
Parameters  Group N (n=4)  Group EAM (n=6)  Group Tel-10 (n=6) 
Body weight (g)  325±5.2  238±3.8**  250±4.2** 
Heart weight (g)  1.28±0.1  1.66±0.2**  0.88±0.16## 
HW / BW (g/kg)  3.4±0.4  6.2±0.5**  4.9±0.24## 
Area of fibrosis (%)  2.8±0.5  54.0±2.4**  35.5±2.1## 
Serum ANG 1-7 (ng/ml)  1.04±1.5  0.68±0.7**  0.96±1.3*# 
 Results are presented as the mean ± S.E.M. HW/BW, ratio of heart weight to body weight; ANG 1-7, angiotensin 1-7; group N, aged 
matched untreated rats; group EAM, rats with heart failure treated with vehicle; group Tel-10, rats with heart failure treated with telmisartan 
10 mg/kg/day, respectively; * P < 0.05 and ** P < 0.01 vs group N; # P < 0.05 and ## P < 0.01 vs group EAM. 
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Figure  1:  Representative  echocardiographic  (M-mode)  images  showing  the  left  ventricular  dimensions.  IVS:  in-
tra-ventricular septum; LVDd: left ventricular dimension in diastole; LVDs: left ventricular dimension in systole. Group N, 
age-matched  untreated  rats;  group  EAM,  EAM  rats  administered  with  vehicle;  group  Tel-10,  EAM  rats  treated  with 
telmisartan (10 mg/kg/day) respectively. Scale bar indicates 1 cm. 
 
 
 
Figure 2: Effects of telmisartan on myocardial protein expressions of inflammatory markers. [2A] Representative Western 
blots showing specific bands for NF-kB, Cox-2, TNF-α and iNOS, and GAPDH as an internal control. An equal amount of 
protein sample (30 g) obtained from whole ventricular homogenate was applied in each lane. These bands are repre-
sentative of five separate experiments. [2B–2E], Bar graph showing the densitometric analysis of the above Western blots. 
The mean density value of NF-kB, Cox-2, TNF-α and iNOS was expressed as a relative ratio to that of GAPDH. Each bar 
represents the mean ± S.E.M of 4 to 6 rats. Group N, age-matched untreated rats; group EAM, EAM rats administered with 
vehicle; group Tel-10, EAM rats treated with telmisartan (10 mg/kg/day) respectively. 
* P < 0.05 and 
**P<0.01 vs group N; 
# P 
< 0.05 and 
## P < 0.01 vs group EAM. 
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Effects of telmisartan on myocardial protein ex-
pressions of ACE-2 and ANG 1-7 mas receptor  
The levels of ACE-2 and ANG 1-7 mas receptor 
in the myocardium were significantly downregulated 
in  group  EAM  rats  (0.7  and  0.5-fold,  respectively) 
compared  with  those  of  group  N  rats  (Fig.  3A-3C). 
After treatment with telmisartan, the levels of ACE-2 
and ANG 1-7 mas receptor in the myocardium were 
upregulated (0.5 and 0.5-fold, respectively) compared 
with those of vehicle-treated rats (Fig. 3A-3C), but the 
effects were significant only in terms of Ang 1-7.  
Effects of telmisartan on NADPH oxidase subu-
nits 
The myocardial protein levels of 3-NT, p47phox, 
p67phox and Nox-4 were significantly upregulated in 
group EAM rats (2.2, 2.2, 2.3 and 3.9-fold, respective-
ly)  compared  with  group  N  rats  (Fig.  4A-4E).  The 
myocardial protein levels of 3-NT, p47phox, p67phox 
and  Nox-4  were  significantly  downregulated  by 
telmisartan  treatment  (2.4,  2.3,  1.2  and  1.3-fold,  re-
spectively)  compared  with  those  in  vehicle-treated 
rats (Fig. 4A-4E).  
 
 
 
Figure 3: Effects of telmisartan on myocardial protein expressions of ACE-2 and ANG 1-7 mas receptor. [3A], Repre-
sentative Western blots showing specific bands for ACE-2, ANG 1-7 mas receptor, and GAPDH as an internal control. An 
equal amount of protein sample (30 g) obtained from whole ventricular homogenate was applied in each lane. These bands 
are representative of three separate experiments. [3B-3C], Bar graph showing the densitometric analysis of the above 
Western blots. The mean density value of ACE-2 and ANG 1-7 mas receptor is expressed as the relative ratio to that of 
GAPDH. Each bar represents the mean ± S.E.M of 4 to 6 rats. Group N, age-matched untreated rats; group EAM, EAM rats 
administered with vehicle; group Tel-10, EAM rats treated with telmisartan (10 mg/kg/day) respectively. 
* P < 0.01 vs group 
N; 
## P < 0.01 vs group EAM. Int. J. Biol. Sci. 2011, 7 
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Figure 4: Effects of telmisartan on myocardial protein expressions of 3-NT, p47phox, p67phox and Nox-4. [4A] Repre-
sentative Western blots showing specific bands for 3-NT, p47phox, p67phox and Nox-4, and GAPDH as an internal control. 
An equal amount of protein sample (30 g) obtained from whole ventricular homogenate was applied in each lane. These 
bands are representative of five separate experiments. [4B–4E], Bar graph showing the densitometric analysis of the above 
Western blots. The mean density value of 3-NT, p47phox, p67phox and Nox-4 was expressed as a relative ratio to that of 
GAPDH. Each bar represents the mean ± S.E.M of 4 to 6 rats. Group N, age-matched untreated rats; group EAM, EAM rats 
administered with vehicle; group Tel-10, EAM rats treated with telmisartan (10 mg/kg/day) respectively.
 **P<0.01 vs group N; 
# P < 0.05 and 
## P < 0.01 vs group EAM. 
 
 
 
Effects of telmisartan on myocardial content of 
ACE-2 and ANG 1-7 mas receptor 
Myocardial  immunoreactivity  for  ACE-2  and 
ANG 1-7 mas receptor was apparently weaker in ve-
hicle-treated rats (Fig. 5A-5B). Telmisartan treatment 
significantly  increased  the  myocardial  content  of 
ACE-2  and  ANG  1-7  mas  receptor  compared  with 
those of vehicle-treated rats (Fig. 5A-5B). 
Effects of telmisartan on superoxide production 
in hearts 
We used the fluorescent probe DHE, which has 
been used to detect intracellular superoxide formation 
[28, 29]. Fig. 5D shows the intracellular red fluores-
cence due to the intercalation of ethidium into DNA in 
the heart of vehicle-treated rats after 21days of myosin 
immunization  compared  to  the  normal  rats.  Myo-
sin-induced  enhancement  of  ethidium  fluorescence 
was  inhibited  in  telmisartan  treated  rats  compared 
with that of vehicle-treated rats (Fig. 5D), indicating 
an overall reduced oxidative stress.  
Effects of telmisartan on myocardial protein ex-
pression of ER stress markers 
The protein levels of TRAF-2, CHOP and GRP-78 
in the myocardium were significantly upregulated in 
group  EAM  rats  (2.8, 1.3 and  1.6-fold,  respectively) 
compared with group N rats (Fig. 6A-6D). The protein 
levels of TRAF-2, CHOP and GRP-78 were downreg-
ulated in telmisartan treated rats (2.0, 1.3 and 1.4-fold, 
respectively) compared with those of vehicle-treated 
rats (Fig. 6A-6D). In addition, we have measured the 
myocardial  content  of  GRP-78  by  Immunofluores-
cence,  and  the  myocardial  immune  reactivity  for Int. J. Biol. Sci. 2011, 7 
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GRP-78  was  significantly  increased  in  the  vehi-
cle-treated rats compared with those of group N rats 
(Fig. 5E) and these increased immuno reactivity was 
significantly  decreased  by  telmisartan  treated  rats 
than those in group EAM rats (Fig. 5E).  
 
 
 
 
Figure 5: Effects of telmisartan on myocardial content (ACE-2 and ANG 1-7), apoptosis, superoxide production and ER 
stress in rats with EAM induced by autoimmune myocarditis. [5A-5B] Immunohistochemistry of angiotensin converting 
enzyme (ACE-2), angiotensin (ANG) 1-7 mas receptor [counterstained with hematoxylin; ×400]. [5C], Immunofluorescence 
determination of caspase-3 positive cells. [5D] In situ superoxide production (bright area) using DHE-staining in the rat 
myocardium (x200). [5E] Immunofluorescence determination of glucose regulated protein-78 (GRP-78) (x100). Group N, 
age-matched  untreated  rats;  group  EAM,  EAM  rats  administered  with  vehicle;  group  Tel-10,  EAM  rats  treated  with 
telmisartan (10 mg/kg/day) respectively. Scale bar indicates 20 μm. Int. J. Biol. Sci. 2011, 7 
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Figure 6: Effects of telmisartan on myocardial protein expressions of TRAF-2, CHOP and GRP-78. [6A], Representative 
Western blots showing specific bands for TRAF-2, CHOP, GRP-78, and GAPDH as an internal control. An equal amount of 
protein sample (30 g) obtained from whole ventricular homogenate was applied in each lane. These bands are repre-
sentative of four separate experiments. [6B-6D] Bar graph showing the densitometric analysis of the above Western blots. 
The mean density value of TRAF-2, CHOP and GRP-78 is expressed as the relative ratio to that of GAPDH. Each bar 
represents the mean ± S.E.M of 4 to 6 rats. Group N, age-matched untreated rats; group EAM, EAM rats administered with 
vehicle; group Tel-10, EAM rats treated with telmisartan (10 mg/kg/day) respectively; 
* P < 0.01 vs group N; 
# P < 0.05 and 
## 
P < 0.01 vs group EAM. 
 
 
Effects of telmisartan on cardiac apoptosis  
The protein levels of caspase-3 and 7 in the my-
ocardium  were  significantly  upregulated  in  group 
EAM rats (4.2 and 5-fold, respectively) compared with 
group N rats (Fig. 7A-7C). Though, these levels were 
attenuated in telmisartan treated rats (0.5 and 4.5-fold, 
respectively) compared with those of vehicle-treated 
rats (Fig. 7A-7C), but the effect was significant only 
in-terms  of  caspase-7.  In  addition  we  observed  de-
creased  caspase-3  positive  cells  in  the  telmisartan 
treated group compared with those of vehicle-treated 
rats  (Fig.  5C).  In  contrast,  myocardial  protein  level 
apoptotic  regulator  molecule  bcl-2  was  significantly 
decreased  in  vehicle-treated  rats  than  group  N  rats 
(Fig. 7D) and these levels were significantly increased 
in the telmisartan treated rats. 
Effects of telmisartan on myocardial protein ex-
pressions of signaling pathways 
Myocardial  protein  expression  of  phospho-p38 
MAPK,  phospho-JNK,  phospho-ERK  and  phos-
pho-p38  MAPKAPK-2  was  markedly  increased  in 
group EAM rats (1.6, 4.6, 4.1 and 1.8-fold, respective-
ly) compared with that in group N rats (Fig. 8A-8E) 
and these protein levels were significantly decreased 
by  telmisartan  treatment  (1.4,  1.4,  1.8  and  1.8-fold, 
respectively) compared with those of vehicle-treated 
rats (Fig. 8A-8E).  
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Figure 7: Effects of telmisartan on myocardial apoptosis and its marker molecules. [7A-7C] Representative Western blots 
showing specific bands for caspase-3, caspase-7 and bcl-2, and GAPDH as an internal control. An equal amount of protein 
sample (30 g) obtained from whole ventricular homogenate was applied in each lane. These bands are representative of 
four separate experiments. [7A-7C], Bar graph showing the densitometric analysis of the above Western blots. The mean 
density value of caspase-3, caspase-7 and bcl-2 is expressed as the relative ratio to that of GAPDH. Each bar represents the 
mean ± S.E.M of 4 to 6 rats. Group N, age-matched untreated rats; group EAM, EAM rats administered with vehicle; group 
Tel-10, EAM rats treated with telmisartan (10 mg/kg/day), respectively; 
* P < 0.05 and 
**P<0.01 vs group N; 
## P < 0.01 vs 
group EAM.  
 
Discussion  
From previous studies, using angiotensin type 1 
receptor (AT1R) blockers were found to be effective in 
improving cardiac function and in preventing myo-
cardial  remodeling  in  various  experimental  heart 
failure models. However, whether AT1R blockers are 
better than ACE inhibitors on heart failure remains 
unknown, and it may differ according to the patho-
genesis of heart failure. The results of present study 
demonstrate  that  the  treatment  with  oral  ARB 
(telmisartan) improved both systolic (+dP/dt, %  EF 
and % FS) and diastolic (−dP/dt and LVEDP) func-
tions, increased in neurohormonal parameter such as 
serum  ANG  1-7,  and  reduced  the  severity  of  acute 
EAM  in  rats,  and  that  the  cardioprotection  of  ARB 
occur  via  the  modulation  of  ACE2/ANG  1-7/Mas 
receptor expression with marked suppression of in-
flammation, oxidative stress, endoplasmic reticulum 
(ER)  stress,  myocardial  apoptosis  and  signaling 
pathways. 
Over the last decade, evidence accumulated that 
ANG  1–7  has  cardiovascular  protective  effects  [31] 
and counteracts detrimental effects of ANG II under 
pathophysiological conditions [32]. These effects may 
relate to the heptapeptide’s ability of vasorelaxation 
post  myocardial  infarction  and  its  blood  pressure 
lowing effects under hypertensive conditions. It has 
been  reported  that  loss  of  ACE-2  accelerates  mala-
daptive  LV  remodeling  in  response  to  myocardial 
infarction  through  increased  production  of  inflam-
matory  cytokines  such  as  interferon-gamma,  inter-Int. J. Biol. Sci. 2011, 7 
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leukin-6,  and  the  chemokine,  monocyte  chemoat-
tractant protein-1, as well as increased phosphoryla-
tion of ERK1/2 and JNK1/2 signaling pathways and 
treatment  with  irbesartan  reduced  nicotina-
mide-adenine dinucleotide phosphate (NADPH) ox-
idase  activity,  infarct  size,  matrix  matelloproteinase 
activation, and myocardial inflammation, ultimately 
resulting  in  improved  post-myocardial  infarction 
ventricular function [33]. Further, ANG-(1-7) or cap-
topril  treatment  reduced  the  expression  of  several 
genes  of  inflammation  involved  in  the  NF-kappaB 
signaling pathway, as a result it reduces cardiac is-
chemia-induced dysfunction in diabetic hypertensive 
rats  [34].  Interestingly,  we  could  observe  increased 
myocardial protein levels of inflammatory cytokines, 
such as TNF-α, Cox-2, iNOS, and NF-kB in rats with 
EAM, and these changes in protein levels were sig-
nificantly decreased by telmisartan treated group (Fig. 
2A-2E). Further, we have observed an increased ex-
pression of ACE-2 and ANG 1-7 mas receptor in the 
rats treated with ARBs compared with those of vehi-
cle-treated rats (Fig. 3 and 5A-5B). These results sug-
gest that reduced levels of ACE-2/ANG1-7 facilitates 
adverse myocardial remodeling in EAM rats by po-
tentiating  the  ANG-II  effects  by  means  of  the  AT1 
receptors,  and  treatment  with  telmisartan  prevents 
myocardial  remodeling  through  augmentation  of 
ACE-2/ANG1-7, as a result it decreases the inflam-
matory events in EAM rats. 
 
 
Figure  8: Myocardial expressions of phospho-p38 MAPK, phospho-JNK, p38 MAPK, JNK, phospho-ERK, ERK, phos-
pho-p38MAPKAPK-2 and p38-MAPKAPK-2. [8A] Representative western blots showing specific bands for phospho-p38 
MAPK, phospho-JNK, p38 MAPK, JNK, phospho-ERK, ERK, phospho-p38MAPKAPK-2 and p38-MAPKAPK-2 as an internal 
control. An equal amount of protein sample (30 g) obtained from whole ventricular homogenate was applied in each lane. 
These bands are representative of eight separate experiments. [8B-8E], Bar graph showing the densitometric analysis of the 
above  Western  blots.  The  mean  density  value  of  phospho-p38  MAPK,  phospho-JNK,  phospho-ERK  and  phos-
pho-p38MAPKAPK-2 was expressed as a ratio relative to that of p38 MAPK, JNK, ERK and p38-MAPKAPK-2. Each bar 
represents the mean ± S.E.M of 4 to 6 rats. Group N, age-matched untreated rats; group EAM, EAM rats administered with 
vehicle; group Tel-10, EAM rats treated with telmisartan (10 mg/kg/day) respectively; 
* P < 0.01 and 
**P<0.01 vs group N; 
# P 
< 0.05 and 
## P < 0.01 vs group EAM. Int. J. Biol. Sci. 2011, 7 
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Several  studies  have  described  that  oxidative 
stress, apoptosis is involved in the pathogenesis and 
development of cardiac diseases including heart fail-
ure,  atherosclerosis  and  hypertension  [35-37].  Many 
studies have shown that blockade of ANG-II signifi-
cantly reduces the levels of proinflammatory media-
tors and oxidative stress products in various models 
of inflammation [38-41]. Recent study reported that, 
local RAS was found to be highly activated as mani-
fested by the increased ACE expression and ANG-II 
level, and decreased ACE-2 expression and ANG 1-7 
level in the heart [42]. As the key peptide of the RAS, 
ANG-II exerts a variety of effects via its type 1 recep-
tor, including vasoconstriction, sodium retention, cell 
proliferation  and  apoptosis,  proinflammation  and 
oxidative  stress  [43-44].  Overproduction  of  reactive 
oxygen species (ROS) causes oxidative stress, and has 
been  implicated  in  the  pathophysiology  of  cardio-
vascular disease. Contrary to ANG-II, ANG 1-7 has 
vasodilation, anti-inflammation and anti-proliferation 
effects.  Benter  et  al.,  reported  that  treatment  with 
ANG 1–7 constitutes a potential therapeutic strategy 
to  alleviate  NOX-mediated  oxidative  stress  and  to 
reduce renal dysfunction in diabetic hypertensive rats 
[45]. In addition, irbesartan, an AT1 receptor blocker, 
diminished maladaptive LV remodeling in response 
to  myocardial  infarction  through  reduced  NADPH 
oxidase activity and upregulation of ACE-2 levels [30]. 
In  the  present  study,  we  confirmed  the  utility  of 
ACE-2/ANG  1-7  to  alleviate  ROS  activation  in  the 
myocardial remodeling in EAM rats by several inde-
pendent  indices  such  as  immunohistological  and 
western  immunoblotting  detection  of  ACE-2,  ANG 
1-7 mas receptor  expression, superoxide production 
measured by DHE staining, apoptosis and increased 
expression of NADPH oxidase subunits (Figs 3, 5 and 
7),  respectively.  The  expression  of  NADPH  oxidase 
subunits  were  significantly  downregulated  by 
telmisartan treatment in comparison with that of ve-
hicle-treated rats (Fig 4). Our present data may link 
the  involvement  of  ACE-2/ANG  1-7  axis  in  the  at-
tenuation  of  myocardial  remodeling  process  via,  at 
least in part, a pathway of reduced ROS activation. On 
the basis of our results, we consider that telmisartan 
protects the heart from myocarditis partly through the 
suppression of apoptosis and oxidative stress. 
Multiple signal transduction pathways mediated 
through G-protein–coupled receptors have been im-
plicated in cardiac dysfunction and hypertrophy un-
der  the  pathophysiological  circumstances  of  heart 
failure  [46].  The  endoplasmic  reticulum  (ER)  is  a 
highly  dynamic  organelle  that  participates  in  the 
folding of secretory and membrane proteins. Several 
signaling  pathways  are  initiated  to  cope  with  ER 
stress, which are designated as the unfolded protein 
response (UPR) [47]. Studies reported that, induction 
of GRP78 has been widely used as a marker for ER 
stress and the onset of UPR [48]. Furthermore, GRP78 
serves as a master modulator for the UPR network by 
binding to the ER stress sensors such as protein kinase 
R (PKR)-like ER kinase, inositol requiring enzyme 1 
(IRE1),  and  activating  transcription  factor  6  (ATF6) 
and inhibiting their activation [48]. Oxidative stress, 
hypoxia,  and  enhanced  protein  synthesis  in  failing 
hearts  could  all  potentially  enhance  ER  stress. 
Emerging  data  has  indicated  that  excessive  and/or 
prolonged  ER  stress  leads  to  the  initiation  of  the 
apoptotic  processes  promoted  by  transcriptional  in-
duction  of  CHOP  or  by  the  activation  of 
c-Jun-N-terminal  kinase  (JNK)  and/or  caspa-
se-12-dependent pathway [49]. On the other hand, it 
has been reported that ANG-II upregulated ER chap-
erones  and  induced  apoptosis  in  cultured  adult  rat 
cardiac myocytes [50]. In contrast, ANG-(1–7) reduces 
the  agonist-mediated  increase  in  protein  synthesis 
and  mitogen-activated  protein  kinases  (MAPK)  sig-
naling  in  cultured  myocytes  and  because  plasma 
ANG-(1–7) levels are increased after treatment with 
AT1 receptor blockers [51-52], suggest that ANG-(1–7) 
may participate in the improvement in cardiac func-
tion.  Furthermore,  Tallant  and  Clark  showed  that 
ANG-(1-7) treatment blocked the ANG II-stimulated 
phosphorylation  and  activation  of  ERK1  and  ERK2 
[12].  Furthermore,  Koka  et  al  demonstrated  that 
treatment with AT1 receptor blocker or blockade of 
ERK1/2 or MAPK by either specific inhibitor was able 
to abolish ANG II-induced ACE2 downregulation in 
human kidney tubular cells which suggest that ANG 
II-induced ACE2 downregulation has been shown to 
be associated with activation of ERK1/2 and p38 MAP 
kinase pathways [53]. Moreover, it has been reported 
that  telmisartan  induced  a  significant  increases  of 
ACE-2 gene and protein expressions in the myocar-
dium of pressure-overloaded rats and also attenuates 
vascular hypertrophy in spontaneously hypertensive 
rats by the modulation of ACE-2 expression with a 
marked reversal of ERK1/2 and JNK phosphorylation 
signaling  pathways  [23-24].  In  the  present  study, 
telmisartan treatment significantly downregulated the 
myocardial  protein  expressions  of  MAPK  signaling 
pathways and ER stress markers including TRAF-2, 
CHOP  and  GRP-78  compared  with  those  of  vehi-
cle-treated rats (Figs. 5E, 6 and 8). Taken together, our 
results  suggest  that  telmisartan  treatments  regulate 
oxidative stress, ER stress and signaling pathways in 
myosin-induced  heart  failure  through  modulating 
ACE-2/ANG1-7/Mas receptor axis. However, atten-
uation  of  myocardial  remodeling  events  through Int. J. Biol. Sci. 2011, 7 
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ACE-2/ANG1-7/Mas  receptor  axis  in  EAM  rats  re-
mains to be determined.  
Our study raises the possibility that, in addition 
to  ANG-II  antagonism,  the  activation  of  the 
ACE-2–ANG-(1–7)–Mas  receptor  axis  might  become 
an  alternative  approach  to  treat  cardiovascular  dis-
ease. In conclusion, our results indicate that telmisar-
tan reduced the severity of EAM significantly and the 
mechanism of disease amelioration by this inhibitory 
agent can be at least partly explained by the suppres-
sion of inflammatory markers, oxidative & ER stress, 
myocardial apoptosis and signaling pathways, which 
resulted in the improvement of myocardial function. 
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